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NTCP-modelsMost new radiation techniques, have been introduced primarily to reduce the dose to normal tissues in
order to prevent radiation-induced side effects. Radiotherapy with protons is such a radiation technique
that due to its superior beam properties compared to photons enables better sparing of normal tissues.
This paper describes a stepwise methodology to select patients for proton therapy when the primary aim
is to reduce side effects. This method has been accepted by the Dutch health authorities to select patients
for proton therapy. In addition, an alternative method is described in case randomised controlled trials
are considered not appropriate.
 2013 Elsevier Ireland Ltd.Radiotherapy and Oncology 107 (2013) 267–273 Open access under CC BY-NC-NDRadiotherapy with protons is a promising technology in the
ﬁeld of modern radiation oncology. From a physical point of view,
radiotherapy with protons has important advantages compared to
the currently used photons due to its unique energy absorption
proﬁle. Proton beams are typically manipulated to generate a
spread-out Bragg peak to yield a ﬂat dose proﬁle across the target
volume followed by a rapid decrease to nearly zero dose distally
from the target, which results in highly conformal dose depositions
in the target.
Based on the physical principles of proton beams, there are two
main applications where the superior properties of protons can be
expected to produce a clinical beneﬁt for cancer patients, i.e.
improvement of local tumour control and prevention or reduction
of radiation-induced side effects.
Certain categories of patients treated with photon therapy re-
ceive a radiation dose that is insufﬁcient to fully eradicate the tu-
mour, in particular when this tumour is located close to critical
structures, hampering further dose escalation. By using protons,
the energy dose deposited in the target can be optimised without
simultaneously increasing the dose to critical organs. This strategy
will be particularly useful when dose escalation can be expected to
improve tumour control. For this purpose, conducting randomised
controlled trials (RCT) in order to investigate if dose escalation
with protons results in better local control without enhancingthe dose to critical structures and thus increasing toxicity, would
be the most suitable and valid approach.
A substantial percentage of cancer patients treated with radio-
therapy may suffer from signiﬁcant radiation-induced side effects
negatively impacting quality of life [1–5]. In these cases, protons
might be applied in an attempt to prevent or signiﬁcantly reduce
side effects by decreasing the dose to healthy tissues while main-
taining the dose administered to the target. This approach is based
on the observation that for many critical organs or normal tissues,
the probability of radiation-induced side effects depends on the –
relative and absolute – volumes of Organs at Risk (OARs) receiving
certain doses of radiation [6–12]. Based on the results of numerous
in-silico planning comparative studies, comparing dose distribu-
tions to OARs between photon and proton radiotherapy, it can be
expected that proton radiotherapy will result in a reduction of
radiation-induced side effects [13–21]. When translating these re-
sults from in-silico planning comparisons (ISPC) an optimal study
design is required to clinically validate the beneﬁt of protons when
speciﬁcally applied to prevent side effects rather than improve tu-
mour control [22].
Some late radiation-induced complications have very long la-
tency times, e.g. the development of cardiovascular complications
after irradiation for breast cancer generally takes at least 5 years,
and the incidence in particular continues to increase over twenty
years after initial treatment [23–25]. In such cases, an RCT would
take at least 15–20 years to generate useful information regarding
the primary endpoint. For such late endpoints, it would be unreal-
istic to conduct an RCT, given that radiotherapy is a rapidly
268 Selection of patients for protonsevolving technology where further improvement can be expected
to occur much faster and the results based on outdated technology
investigated in such RCT will never be applicable in future clinical
practice.
Several authors have argued that in the case of proton radio-
therapy, applying the standard RCT methodology in such toxic-
ity-reducing trials would result in randomising patients between
two radiation delivery technologies that yield the same tumour
dose distribution and will thus yield the same tumour control
probability, but where one technique would result in a predictably
left-shifted (unfavourable) dose-toxicity curve. Such a situation is
inconsistent with the general ethical prerequisite for RCT’s, the
principle of ‘equipoise’ (balanced uncertainty) [26], where a certain
outcome may be expected, but must not be predictable based on
reasonably validated prediction models. This is particularly true
in situations, where the predictable difference in toxicity is rela-
tively large with an expected major impact on quality of life (e.g.
severe visual impairment). As a consequence, RCT’s investigating
the added value of protons compared to photons with regard to
reduction of side effects, run the risk of being ethically
compromised.
Considering that RCT’s are not always the most suitable meth-
odology or practically feasible for validating proton radiotherapy,
the following questions arise: (1) how to individually tailor the
indication criteria in order to select patients who are expected to
beneﬁt from radiotherapy with protons in terms of reducing the
risk of radiation-induced side effects, and (2) can we apply a meth-
odologically sound approach other than RCT’s for the clinical vali-
dation of the predicted beneﬁt when patients are actually treated
with protons, when an RCT is considered not feasible.
Addressing these questions, a stepwise approach, referred to as
the model-based approach, has been introduced in the Netherlands
to properly select patients that will beneﬁt from protons in terms
of prevention of side effects and, subsequently, to validate the
clinical beneﬁt of protons compared to photons in case an RCT is
considered inappropriate for reasons mentioned above. This
model-based approach, which has been adopted by the Health
Council of the Netherlands to select patients for proton radiother-
apy will be described and discussed in the present paper.0%
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Fig. 1. Example of a Normal Tissue Complication Probability (NTCP) model describing
relevant dose distribution parameter (in this case the mean parotid dose).The model-based approach
The model-based approach consists of two consecutive phases:
phase a, aiming at the selection of patients who may beneﬁt from
protons, and phase b, aiming at the clinical validation of proton
therapy by so-called sequential prospective observational cohort
(SPOC) studies using appropriate historical comparisons as a refer-
ence or by RCT’s in selected situations.Phase a: model-based indications
Phase a of the model-based approach consists of 3 steps,
including: (1) the development and validation of Normal Tissue
Complication Probability (NTCP) models in patients treated with
state-of-the-art photon radiotherapy; (2) individual in silico plan-
ning comparative studies [21], and (3): estimation of the potential
beneﬁt of the new radiation technique in reducing side effects by
integrating the results of ISPC into NTCP-models. The main purpose
of these 3 steps is to select patients that will most likely beneﬁt from
protons compared to photons in terms of NTCP-value reductions.Step 1: NTCP models
The basic principle in the development of most new radiation
delivery techniques is to obtain the required dose to the target
with the lowest possible dose to the normal tissues, assuming a
relationship between dose distributions in OARs and the develop-
ment of radiation-induced side effects. These relationships are gen-
erally described by NTCP-models. In general, the estimated risk for
a given side effect, i.e. the NTCP-value, will increase with increas-
ing dose to and increasing volume within an OAR that receives a
certain dose (Fig. 1). The dose-volume parameter or parameters
that are most important may vary widely between different side
effects, e.g. the mean dose to the parotid glands is the most impor-
tant prognostic factor for the development of hyposalivation and
xerostomia [7], while for radiation pneumonitis, different dose-
volume parameters are important, such as the mean dose to the
lungs, the V5 (i.e. the percentage of the volume of the lungs that
receives a dose of 5 Gy or more) and the V20 [11]. Moreover, the
risk of some side effects may depend onmore than one dose-volume40 50 60 70
tid dose (Gy)
the risk estimation on a given side effect (NTCP-value) as a function of the most
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pends on the mean dose to the superior pharyngeal constrictor
muscle and the mean dose to the supraglottic area) [27]. The most
reliable dose-volume parameters are generally obtained from pro-
spective cohort studies and should preferably be validated in inde-
pendent cohorts. When the most important dose-volume
parameters are established, radiotherapy treatment planning can
be optimised by reducing these speciﬁc parameters as much as
possible, without jeopardising the required dose to the targets
and without enhancing the dose to other critical structures. Often
the performance of the predictors can be further improved by add-
ing patient related (e.g. general status, age) or environment related
(e.g. concomitant chemotherapy) variables producing multivari-
able NTCP-models that can be expressed as nomograms [28,29].Step 2: in silico planning comparative (ISPC) studies
The knowledge gained from NTCP-models can be used to iden-
tify patients who are expected to beneﬁt from protons, using com-
puter-based studies in which the dose distributions obtained with
protons are simulated and compared with the best currently
achievable photon treatment in each individual patient (individual
tailoring of indications based on ISPC studies) (Fig. 2) [13–21]. ISPC
studies eventually tell us the differences in the relevant dose distri-
bution parameters to the targets and OARs between different radi-
ation delivery techniques (e.g. between 3D-CRT and IMRT; IMRT
and protons) either on a population level or on the level of individ-
ual patients. However, these differences in dose distributionSUPERIOR PHARYNGEAL 
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Fig. 2. Example of an individual In Silico Planning Comparative study in a patient with
aiming at sparing to the parotid glands, the superior pharyngeal constrictor muscle (su
modulated proton therapy (SWIMPT). Efforts were made to reduce the dose to the parot
PCM and supraglottic areas based on the NTCP-model published by Christianen et al. [27]
this case, a marked reduction of the dose to the supraglottic area and both parotid glands
because this OAR partly overlapped with the PTV. Upper left panel: Transversal CT-slides
protons and moderate sparing of the superior PCM. Upper right panel: sagittal CT-slides c
(yellow area). Lower left panel: dose volume histograms of the superior PCM and sup
histograms of the parotid glands comparing photons with protons.parameters do not automatically entail a beneﬁt in terms of a
reduction in the risk of a given side effect. This is particularly the
case if the development of a side effect depends on more than
one dose-volume parameter, or if other confounding factors, such
as the administration of concomitant chemotherapy, beside dose
distributions inﬂuence the development of radiation-induced side
effects, e.g. as has been found for rectal complications after radio-
therapy for prostate cancer [30] and for radiation esophagitis after
radiotherapy for lung cancer [31].Step 3: estimation of the clinical beneﬁt
The ﬁnal step in phase awill be to determine to what extent the
advantage in physical dose distribution will translate into a clini-
cally relevant beneﬁcial effect by integrating the outcome of an
individual ISPC-study into NTCP-models. In other words, will the
reduction in dose translate into a lower NTCP-value? This step is
required as similar absolute or relative reductions in the most rel-
evant dose distribution parameters will not always translate into
the same amount of reduction in NTCP values as illustrated in
Fig. 3. The clinically relevant toxicity-reduction depends on the
shape of the NTCP-curve and on the initial value of the dose distri-
bution parameter (Fig. 3). Moreover, in case the risk of side effects
depends on other factors as well, e.g. the administration of concur-
rent chemoradiation, the same reduction in dose could translate
into markedly different NTCP-value reductions. For some side ef-
fects, the risk estimation may depend on two dose distribution fac-
tors, such as in the case of grade 2–4 swallowing dysfunctionz
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cT3N0M0 oropharyngeal cancer. In this case swallowing-sparing IMRT (SWIMRT),
perior PCM) and supraglottic area, was compared to swallowing-sparing intensity
id glands as much as possible and subsequently to reduce the dose to the superior
. Details on the SWIMRT and SWIMPT techniques have been previously described. In
could be obtained with protons. The superior PCM could be spared to a lesser extent
comparing photons with protons. There is a clear sparing of both parotid glands with
omparing photons with protons particularly illustrating sparing of supraglottic area
raglottic area comparing photons with protons. Lower right panel: dose volume
Fig. 3. Translation of the results of the individual ISPC-study depicted in Fig. 2 with regard to xerostomia. The reduction of the mean parotid dose from 30.1 Gy to 18.4 Gy (red
arrow: example Fig. 2) corresponds with an estimated NTCP-value reduction for severe xerostomia from 50% to 24% according to the NTCP-model published by Semenenko.
However, exactly similar absolute dose reductions (red arrow: other example) result in a minimal estimated NTCP-value reduction when the initial dose is much higher, due
to the shape of the NTCP-curve.
270 Selection of patients for protons(Fig. 4) [27]. In this way, the NTCP-value reduction for each indi-
vidual patient can be estimated. Indeed, recent ISPC studies have
shown that the estimated NTCP-reductions of protons compared0%
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Fig. 4. Translation of the results of the individual ISPC-study depicted in Fig. 2 with regar
mean dose to the superior PCM and to the supraglottic area. The upper (dark blue) and lo
and the risk on grade 2–4 RTOG swallowing dysfunction when the mean supraglottic do
model described by Christianen et al. [27] the dose reductions to these two structures obwith photons may vary widely among individual patients with
apparently similar tumours (primary site and stage), e.g. in clini-
cally node-negative oropharyngeal cancer patients, the NTCP-value40 50 60 70
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d to swallowing dysfunction RTOG grade 2–4. This toxicity endpoint depends on the
wer curves (light blue) describe the relationship between the mean dose to the PCM
se is 34.5 Gy (SWIMRT) and 13.5 Gy (SWIMPT), respectively, according to the NTCP-
tained with SWIMPT results in an estimated NTCP-value reduction from 21% to 7%.
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Therapy (IMPT) as compared to IMRT varied between 8% and 28%
for hyposalivation and between 4% and 18% among patients for pa-
tient-rated xerostomia [32–34]. The percentage of individuals who
will be ultimately selected for proton radiotherapy will then de-
pend on the threshold chosen for the NTCP-value reductions of
the side effects in question. If, in this example, a threshold of 10%
NTCP-value reduction would be applied for hyposalivation, 70%
of the patients would be selected for proton radiotherapy.
Whenever the integration of the results of an individual ISPC
study indicates that proton therapy is not expected to provide a
clinically relevant NTCP-value reduction, there is consequently
no reason to select this patient for proton therapy. Alternatively,
in that case, the available best photon technique should be offered.
In this respect, it should be emphasised that it does not make sense
to include such patients in an RCT either, as there is no beneﬁt to
be expected from the new technique. In this regard, it would make
sense to introduce this procedure also for selecting patients for
RCT’s. In particular when the results of ISPC studies indicate that
only a relatively small percentage of patients is likely to beneﬁt
from protons, the model-based approach is required to prevent
false negative results.Fig. 5. Schematic overview of the clinical validation using sequential prospective cohort
not available. For each patient included in such a study, a backup proton plan will be mad
with protons. Only patients with estimated NTCP-value reduction beyond the threshold
the near future. After the clinical introduction of protons, only patients with estimated N
results obtained in these patients will be compared to those obtained in the historical con
to similar standard follow up programes.Phase b: clinical validation
Prospective observational study
The abovementioned model-based approach results in the
selection of a speciﬁc cohort of patients that will be eligible for
treatment with protons, i.e. patients with an expected NTCP-value
reduction beyond the deﬁned threshold (e.g. 10%) (Fig. 5). From
this point of view, it would be methodologically unsound to com-
pare the toxicity results of these patients with the results of those
not selected for protons after the same selection procedure. It is
obvious that patients with no or minor overlap, or those with ma-
jor overlap between target volumes and OARs are less likely to
beneﬁt from a more conformal radiation dose delivery. As a conse-
quence, these patients will by deﬁnition bear different risk proﬁles
for radiation-induced side effects and would negatively or posi-
tively bias the results when compared with patients actually se-
lected for proton radiotherapy. Therefore, it is preferable to
follow exactly the same model-based procedure in patients who
have been or currently are treated with photons irrespective of
the outcome of phase a. In this way, the results obtained in a pop-
ulation treated with the current standard (e.g. photon IMRT) can be
considered a valid historical reference for those who will bestudies. The historical control group will be generated in the phase that protons are
e to estimate the NTCP-value reduction in case this patient would have been treated
will be used as nested case controls for patients that will be treated with protons in
TCP-value reduction beyond the threshold will be selected for proton therapy. The
trol group. Data on toxicity and patient-rated symptoms will be assessed according
272 Selection of patients for protonsactually treated with protons. Moreover, this reference population
can be used for the statistical power analysis in order to estimate
the required number of patients needed to be treated with protons
to show a signiﬁcant beneﬁt of the new technique.
An important prerequisite of such an approach is that patients
be subjected to exactly similar follow up procedures in which rel-
evant baseline and treatment characteristics, acute and late radia-
tion-induced morbidity and patient-rated quality of life are
determined in a well structured standardised prospective pro-
gramme. Preferably, similar prospective observational studies
should already be conducted and performed among patients trea-
ted with photons before proton therapy is available to avoid selec-
tion bias based on phase a.
The validity of protons can then be determined in two ways.
First, the difference in the incidences of side effects between the
two techniques can be evaluated by direct comparison. Second,
the NTCP-model obtained in patients treated with photons should
be validated in those treated with protons.Discussion
The model-based indication methodology as described in the
current paper was developed following lively discussions on how
to clinically introduce proton therapy in the Netherlands. The cur-
rent practice in the Netherlands is that new treatment modalities
will only be approved for reimbursement by health care insurance
companies if there is level I-II scientiﬁc evidence. This kind of evi-
dence is not available for proton therapy and it was expected that
it would not be available for the next decade, assuming that RCT’s
for radiation technologies aiming at reduction of side effects will
be difﬁcult to perform for previously discussed reasons and may
be ethically unjustiﬁed due to lack of equipoise. Moreover, RCT’s
or other clinical study designs evidently can only be performed
when sufﬁcient capacity for proton therapy is available. Eventually,
the model-based approach was approved by the Health Council
and by the Health Care Insurance Board that advises the Minister
of Health and guides implementation of procedures into the Dutch
statutory health insurance. This approach will enable future Dutch
proton centres to treat patients with proton therapy, who will
likely proﬁt from this new technology, and whose treatment will
therefore be reimbursed, if predeﬁned nationally agreed-upon
indication criteria based on expected NTCP-value reductions are
met. It will be mandatory that patients treated with protons will
be subjected to standard follow up programmes that are similar
to ongoing follow up programmes for patients currently treated
with photons.
Recently, Vergeer et al. applied the same model-based approach
to estimate the beneﬁt of IMRT over 3D-CRT in patients with head
and neck cancer [35]. In that study, the authors showed that the
reduction of the mean dose to the salivary glands as obtained by
IMRT indeed resulted in lower estimates of patient-rated and phy-
sician-rated xerostomia. Later on, similar effects were found in a
number of RCT’s [36].
It should be clearly emphasised that we do not intend to prop-
agate this methodology as an alternative for RCT’s in all circum-
stances, rather than to use this as the optimal approach when an
RCT is considered not feasible or even inappropriate. In this regard,
it is important to notice that there are some methodological prob-
lems that may hamper the interpretation of the results.
First, as the comparison between patients treated with photons
and protons using sequential prospective cohort studies will be
mainly historical, selection of patients for radiotherapy may
change over time. It cannot be excluded that this may inﬂuence
NTCP-models and thus the outcome in terms of side effects.
Currently, most NTCP-models only include dose distributionparameters, while other independent prognostic or confounding
factors are generally not taken into account. However, some
authors showed that the relationship between dose distribution
parameters and side effects may differ across different patient pop-
ulations [30]. Moreover, changes in dose distributions due to dif-
ferent radiation delivery techniques may also affect the
predictive power of NTCP models, as recently shown for patient-
rated xerostomia and sticky saliva in head and neck cancer patients
treated with either 3D conformal radiotherapy or IMRT [32–34].
Therefore, NTCP-models developed in patients treated with pho-
tons should always be validated among those treated with protons,
prior to the direct comparison of toxicity rates.
For some radiation-induced side effects the precise association
between the dose-volume parameters is less clear, and therefore
the translation of observed differences in dose distributions be-
tween protons and photons into clinical beneﬁts remains to be
determined. In such cases, conducting an RCT is still the best meth-
odology to test the clinical beneﬁt of protons over photons. The
same approach applies to relatively mild side effects, where other
issues, such as cost-effectiveness, may become more important.
Second, conclusions from ISPC studies regarding the added va-
lue of protons can only be justiﬁed in case of straightforward com-
parisons with photons, meaning that the reference technique
should at least include the most advanced and currently available
photon techniques, such as IMRT or tomotherapy [21].
Another important prerequisite for a proper design of ISPC stud-
ies is the deﬁnition of appropriate endpoints, i.e. the most relevant
dose-volume parameters following from NTCP-modelling studies,
and to use these parameters with properly chosen dose constraints
for treatment planning optimisation for all techniques included in
the analysis. Only in this way can the results coming from ISPC
studies be used to translate the dose distribution advantages of
protons compared to photons into a clinical beneﬁt.
Third, the model-based approach to select patients for protons
assumes a similar dose distribution to the target and thus similar
locoregional control rates as have been obtained with the currently
used photons. However, in some patient groups, e.g. in head and
neck cancer, several studies have reported that patient’s anatomy
may signiﬁcantly change during a course of fractionated radiation
regarding both the tumour volume and target volumes as well as
the surrounding normal healthy tissues [37–38]. Such changes
are important when highly conformal treatment planning tech-
niques like protons are considered and may result in marked dif-
ferences between the planned and the actually delivered dose
distribution [39]. As protons are more sensitive to variations in
density heterogeneities along their beam path and therefore to pa-
tient setup errors, these changes may in some cases severely jeop-
ardise adequate dose coverage to the target and thus hamper
locoregional control. In addition, daily set up errors may also cause
deviations between the actually given dose and the prescribed
dose. These problems, however, account for both RCT’s and
sequential prospective cohort studies. Therefore, clinical validation
studies require extensive measures to ensure adequate target
doses, including smart beam set up conﬁgurations, robust planning
techniques (e.g. Distal Edge tracking, Probabilistic Planning [39–
43]), routine image-guided radiotherapy and plan adaptation and
extensive quality assurance programmes.Conclusion
Radiotherapy with protons is a promising radiation technique,
which can be used to reduce the dose to OARs, resulting in less
radiation-induced side effects with similar dose to the target and
subsequent locoregional tumour control. For the introduction of
proton radiotherapy a two-phase model-based approach has been
J.A. Langendijk et al. / Radiotherapy and Oncology 107 (2013) 267–273 273adopted by the Dutch Health Council and the Dutch Health Care
Insurance Board that permits concomitant validation of the tech-
nique. Patients will be eligible for proton treatment in the Nether-
lands, if individually applied validated NTCP models predict
clinically relevant less toxicity. Method and results will be vali-
dated using sequential prospective cohort studies.
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